CONMED Corporation
CNMDHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. With a market capitalization of $1.48B, it sits in small-cap territory. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as powered resection instruments, fluid management and visualization systems, and related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries.
Market Cap
$1.48B
Beta
0.94
P/E (TTM)
26.62
P/E (Fwd)
10.30
EPS (TTM)
$1.85
EPS (Fwd)
$4.78
ROE
5.5%
ROA
4.1%
Cash
$37.3M
Total Debt
$834.2M
Free CF
$131.4M
52W Change
4.0%
Annual Financials
Cash vs Debt
Where CNMD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CNMD finished 12.23% above its 150-day moving average ($41.03) and 11.77% above its 200-day moving average ($41.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CNMD overbought or oversold?
At the October 20, 2026 close, CNMD's RSI(14) was 47.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CONMED Corporation carries $834.2M in total debt against $37.3M in cash reserves — debt is roughly 22.3x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $131.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 5.5% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.1% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $1.05B (2022) to $1.37B (2025), reflecting a 31% increase over the period.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. No single metric tells the full story. Reviewing CNMD's risk profile alongside its fundamentals and technical indicators provides a more complete picture.